Share on StockTwits

Covidien plc (NYSE:COV) VP Coleman N. Lannum III purchased 3,338 shares of the stock on the open market in a transaction dated Wednesday, August 27th. The stock was purchased at an average price of $87.23 per share, for a total transaction of $291,173.74. Following the completion of the purchase, the vice president now directly owns 16,052 shares of the company’s stock, valued at approximately $1,400,216. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Covidien plc (NYSE:COV) traded down 0.44% on Thursday, hitting $86.70. The stock had a trading volume of 2,617,271 shares. Covidien plc has a one year low of $59.17 and a one year high of $92.68. The stock has a 50-day moving average of $87.74 and a 200-day moving average of $77.77. The company has a market cap of $39.167 billion and a price-to-earnings ratio of 26.27.

Covidien plc (NYSE:COV) last announced its quarterly earnings data on Friday, July 25th. The company reported $1.04 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.00 by $0.04. The company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the company posted $0.91 earnings per share. Covidien plc’s revenue was up 4.3% compared to the same quarter last year. On average, analysts predict that Covidien plc will post $4.02 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Covidien plc in a research note on Monday, July 28th. They now have a $101.00 price target on the stock, up previously from $81.00. Separately, analysts at Leerink Swann raised their price target on shares of Covidien plc from $93.00 to $95.00 in a research note on Monday, July 28th. They now have a “market perform” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Covidien plc from $71.00 to $95.00 in a research note on Monday, July 28th. Eleven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $87.54.

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.

Receive News & Ratings for Covidien plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien plc and related companies with Analyst Ratings Network's FREE daily email newsletter.